Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta 42 secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta 42 in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta 42 increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that mice coexpressing FAD mutant APP and PS1 transgenes exhibit additive increases in A 𝛃 42 production (Borchelt et al., 1996, 1997; Citron et al., 1997; Holcomb et al., 1998), althoughrarely have more than two A 𝛃 42 -elevating FAD mutations been combined in transgenic animals.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Citron et al., 1997
In the citing paper
“each of these genetic forms of AD either selectively increases the extracellular concentration of A42 (Suzuki et al., 1994;Borchelt et al., 1996;Duff et al., 1996;Scheuner et al., 1996;Citron et al., 1997) or increases both A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Citron et al., 1997
In the citing paper
“familial EOAD mutations in PSEN1 and PSEN2 typically result in an increased production of longer and more aggregation-prone derivatives of APP such as Aβ1–42 [47–49].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [47]
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citationEndoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80291-3 · Cited by 1,013
Self-citationPrusiner, S. B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90134-z · Cited by 871
Self-citationAmyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Self-citationRadzicka, A., & Wolfenden, R. (1988) · Biochemistry · doi:10.1021/bi00405a042 · Cited by 606
Cited by
Items 101–200 of 1,002
Lazarov, O., Lee, M., Peterson, D. A., & Sisodia, S. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09785.2002 · Cited by 302
“…and PS2) (Price and Sisodia, 1998; Selkoe, 2001); FAD-linked APP or presenilin variants cause disease by enhancing the levels, length, or fibrillogenic properties of A peptides (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997) and their subsequent deposition.”
BackgroundSelf-citationGolde, T. E., Eckman, C. B., & Younkin, S. G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00043-0 · Cited by 244
The role of TNF and its receptors in Alzheimer's disease
Perry, R. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00291-3 · Cited by 297
“The three genes demonstrating autosomal dominant transmission which have been found to cause AD in primarily early-onset families may also be involved in this inflammatory model, since amyloid precursor protein (APP), presenilin 1, and presenilin 2, are proposed to cause AD by increasing the production of amyloid (A )…”
BackgroundMonoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Babić Leko, M., Wray, S., Harrington, C. R., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 289
“All PSEN mutations lead to an increase in the Aβ42:Aβ40 ratio, although the total quantity of Aβ produced remains constant (Citron et al., 1997; Czech et al., 2000).”
Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo
Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., Hersh, L. B., & Thiele, D. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031520100 · Cited by 294
Jan, A., Gokce, O., Luthi-Carter, R., & Lashuel, H. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803159200 · Cited by 291
Larson, J., Lynch, G., Games, D., & Seubert, P. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01698-4 · Cited by 275
Self-citationHigh-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model
Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Émond, V., Julien, P., & Calon, F. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.022 · Cited by 288
“It was recently shown that all mutations in presenilins that are linked to early - onset familial Alzheimer ' s disease lead to increased A 42 / 40 ratio in post mortem brain samples and within cultured cells transfected with the mutant genes ( Citron et al .”
Fontana, B. D., Mezzomo, N. J., Kalueff, A. V., & Rosemberg, D. B. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.004 · Cited by 272
Lammich, S., Okochi, M., Takeda, M., Kaether, C., Capell, A., Zimmer, A.-K., Edbauer, D., Walter, J., Steiner, H., & Haass, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206872200 · Cited by 287
A decade of modeling Alzheimer's disease in transgenic mice
MCGOWAN, E., ERIKSEN, J., & HUTTON, M. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.03.007 · Cited by 287
Götz, J., Streffer, J. R., David, D., Schild, A., Hoerndli, F., Pennanen, L., Kurosinski, P., & Chen, F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001508 · Cited by 274
The role of Aβ42 in Alzheimer's disease
Younkin, S. G. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80035-1 · Cited by 282
Schmitz, C., Rutten, B. P. F., Pielen, A., Schäfer, S., Wirths, O., Tremp, G., Czech, C., Blanchard, V., Multhaup, G., Rezaie, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63235-x · Cited by 281
Intracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease
Ohyagi, Y., Asahara, H., Chui, D.-H., Tsuruta, Y., Sakae, N., Miyoshi, K., Yamada, T., Kikuchi, H., Taniwaki, T., Murai, H., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2637fje · Cited by 281
Seabrook, G. R., Smith, D. W., Bowery, B. J., Easter, A., Reynolds, T., Fitzjohn, S. M., Morton, R. A., Zheng, H., Dawson, G. R., Sirinathsinghji, D. J. S., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00204-4 · Cited by 256
Molecular genetics of Alzheimer’s disease
St George-Hyslop, P. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00301-7 · Cited by 265
Slow Degradation of Aggregates of the Alzheimer's Disease Amyloid β-Protein by Microglial Cells
Paresce, D. M., Chung, H., & Maxfield, F. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.46.29390 · Cited by 271
Exploring the Etiology of Alzheimer Disease Using Molecular Genetics
Lendon, C. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340059034 · Cited by 273
Hutter-Paier, B., Huttunen, H. J., Puglielli, L., Eckman, C. B., Kim, D. Y., Hofmeister, A., Moir, R. D., Domnitz, S. B., Frosch, M. P., Windisch, M., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.043 · Cited by 229
McLaurin, J., Golomb, R., Jurewicz, A., Antel, J. P., & Fraser, P. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m906994199 · Cited by 266
Self-citationAlzheimer's Disease β-Amyloid Peptide Is Increased in Mice Deficient in Endothelin-converting Enzyme
Eckman, E. A., Watson, M., Marlow, L., Sambamurti, K., & Eckman, C. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200642200 · Cited by 218
Neuronal hyperactivity--A key defect in Alzheimer’s disease?
Busche, M. A., & Konnerth, A. (2015) · BioEssays · doi:10.1002/bies.201500004 · Cited by 266
Alzheimer's disease: a re-examination of the amyloid hypothesis
Neve, R. L., & Robakis, N. K. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01168-5 · Cited by 256
The case described by Alois Alzheimer in 1911
Möller, H.-J., & Graeber, M. B. (1998) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050027 · Cited by 224
Genetic Neurodegenerative Diseases: The Human Illness and Transgenic Models
Price, D. L., Sisodia, S. S., & Borchelt, D. R. (1998) · Science · doi:10.1126/science.282.5391.1079 · Cited by 259
Structural Basis for Increased Toxicity of Pathological Aβ42:Aβ40 Ratios in Alzheimer Disease
Pauwels, K., Williams, T. L., Morris, K. L., Jonckheere, W., Vandersteen, A., Kelly, G., Schymkowitz, J., Rousseau, F., Pastore, A., Serpell, L. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.264473 · Cited by 253
Kimberly, W. T., Xia, W., Rahmati, T., Wolfe, M. S., & Selkoe, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3173 · Cited by 253
Self-citationKuo, Y.-M., Kokjohn, T. A., Beach, T. G., Sue, L. I., Brune, D., Lopez, J. C., Kalback, W. M., Abramowski, D., Sturchler-Pierrat, C., Staufenbiel, M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007859200 · Cited by 246
Aβ1–40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation
Niwa, K., Younkin, L., Ebeling, C., Turner, S. K., Westaway, D., Younkin, S., Ashe, K. H., Carlson, G. A., & Iadecola, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9735 · Cited by 244
Self-citationJeong, Y. H., Park, C. H., Yoo, J., Shin, K. Y., Ahn, S., Kim, H., Lee, S. H., Emson, P. C., & Suh, Y. (2006) · The FASEB Journal · doi:10.1096/fj.05-4265fje · Cited by 238
Zinc takes the center stage: its paradoxical role in Alzheimer’s disease
Cuajungco, M. P., & Fagét, K. Y. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00219-9 · Cited by 242
4 Primate Embryonic Stem Cells
Thomson, J. A., & Marshall, V. S. (1997) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(08)60246-x · Cited by 229
Xia, W., Zhang, J., Perez, R., Koo, E. H., & Selkoe, D. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8208 · Cited by 238
Self-citationSjögren, M., Minthon, L., Davidsson, P., Granérus, A. K., Clarberg, A., Vanderstichele, H., Vanmechelen, E., Wallin, A., & Blennow, K. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070079 · Cited by 239
“Thus, decreased CSF-levels of â-amyloid1–42 are probably results of amyloid deposition in the senile plaques in AD (Citron et al., 1997; Tamaoka et al., 1995), and the increased CSF-tau levels probably reflect axonal degeneration and the formation of neurofibrillary tangles (NFT) in AD-afflicted…”
BackgroundA New Pathogenic Mutation in the APP Gene (I716V) Increases the Relative Proportion of A 42(43)
Eckman, C. B., Mehta, N. D., Crook, R., Perez-tur, J., Prihar, G., Pfeiffer, E., Graff-Radford, N., Hinder, P., Yager, D., Zenk, B., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.12.2087 · Cited by 236
Takeuchi, A., Irizarry, M. C., Duff, K., Saido, T. C., Hsiao Ashe, K., Hasegawa, M., Mann, D. M. A., Hyman, B. T., & Iwatsubo, T. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64544-0 · Cited by 229
Williamson, R., Scales, T., Clark, B. R., Gibb, G., Reynolds, C. H., Kellie, S., Bird, I. N., Varndell, I. M., Sheppard, P. W., Everall, I., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00010.2002 · Cited by 227
“All three genes, -amyloid precursor protein, presenilin 1, and presenilin 2, now known to cause AD have been shown to cause an increase in A production or an increase in the ratio of A 42/A 40, both of which drive aggregation (Scheuner et al., 1996; Citron et al., 1997).”
BackgroundKawahara, M., & Kuroda, Y. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00370-1 · Cited by 224
Behavioral assays with mouse models of Alzheimer's disease: Practical considerations and guidelines
Puzzo, D., Lee, L., Palmeri, A., Calabrese, G., & Arancio, O. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.011 · Cited by 213
Purification and Characterization of the Human γ-Secretase Complex
Fraering, P. C., Ye, W., Strub, J.-M., Dolios, G., LaVoie, M. J., Ostaszewski, B. L., van Dorsselaer, A., Wang, R., Selkoe, D. J., & Wolfe, M. S. (2004) · Biochemistry · doi:10.1021/bi0494976 · Cited by 226
Self-citationLing, Y., Morgan, K., & Kalsheker, N. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00133-x · Cited by 224
Oxidative stress potentiates BACE1 gene expression and A? generation
Tong, Y., Zhou, W., Fung, V., Christensen, M. A., Qing, H., Sun, X., & Song, W. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0255-3 · Cited by 218
“These mutations alter the processing of APP, leading to increased production of Ab, or a 42 amino acid form of Ab with a high propensity for plaque formation, implicating a role for altered APP processing in the pathogenesis of familial AD (Goate et al., 1991; Citron et al., 1992; Suzuki et al., 1994; Citron et al., 1…”
BackgroundDe Jonghe, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.16.1665 · Cited by 223
Genetically engineered pigs as models for human disease
Perleberg, C., Kind, A., & Schnieke, A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.030783 · Cited by 222
“Abnormal processing and clearance of the transmembrane APP by secretase complexes, in part composed of PSEN1 and PSEN2, lead to Aβ senile plaque development (Citron et al., 1997; De Strooper et al., 1998; Wolfe et al., 1999).”
BackgroundIntracellular Mechanisms of Amyloid Accumulation and Pathogenesis in Alzheimer's Disease
Glabe, C. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:137 · Cited by 222
“…1 have similar effects on the ratio of Aβ42 to Aβ40, providing further support for the idea that the longer Aβ1-42 is the real problem in pathogenesis (Scheuner, 1996; Lemere et al., 1996; Duff et al., 1996; Borchcit et al., 1996; Citron et al., 1997; Tomita et al., 1997; Xia et al., 1997).”
The Alzheimer family of diseases: Many etiologies, one pathogenesis?
Hardy, J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2095 · Cited by 220
Regulation of Amyloid Precursor Protein Cleavage
Mills, J., & Reiner, P. B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720443.x · Cited by 221
“…Ab is especially significant to AD pathology, as increased length of the hydrophobic C-terminus has been shown to promote early deposition of fibrillar Ab in familial AD where there is a relative increase in the production of Ab1–42 (Borchelt et al., 1996; Lemere et al., 1996; Citron et al., 1997).”
BackgroundInfluentialRockenstein, E., Mallory, M., Mante, M., Sisk, A., & Masliaha, E. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1247 · Cited by 223
“Furthermore, co-expression of hAPP and mutant (but not wt) PS1 in tg mice results in significant overproduction of Ab1–42 in the brain and accelerated amyloid deposition (Borchelt et al., 1996, 1997; Citron et al., 1997).”
BackgroundNishimura, M., Yu, G., Levesque, G., Zhang, D. M., Ruel, L., Chen, F., Milman, P., Holmes, E., Liang, Y., Kawarai, T., et al. (1999) · Nature Medicine · doi:10.1038/5526 · Cited by 219
“Alzheimer amyloid β(1-42) peptide is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells.”
BackgroundSelf-citationLi, J., Xu, M., Zhou, H., Ma, J., & Potter, H. (1997) · Cell · doi:10.1016/s0092-8674(00)80356-6 · Cited by 172
“…that the presenilins may be involved in gene cell lines, and transgenic mice (Martins et al., 1995; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997). expression is provided by the finding that they function in the Notch signaling pathway in C. elegans (Levitan Consistent with…”
Amyloid-β causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons
Chiba, T., Yamada, M., Sasabe, J., Terashita, K., Shimoda, M., Matsuoka, M., & Aiso, S. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.105 · Cited by 194
Mirochnic, S., Wolf, S., Staufenbiel, M., & Kempermann, G. (2009) · Hippocampus · doi:10.1002/hipo.20560 · Cited by 208
A novel presenilin 1 mutation associated with Pick's disease but not β‐amyloid plaques
Dermaut, B., Kumar‐Singh, S., Engelborghs, S., Theuns, J., Rademakers, R., Saerens, J., Pickut, B. A., Peeters, K., Van Den Broeck, M., Vennekens, K., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20083 · Cited by 212
Mouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213
“Moreover, almost all PSEN1 and PSEN2 mutations in FAD cause an increase in the Aβ42/Aβ40 ratio (Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997; Tomita et al., 1997; Table 2).”
BackgroundMolecular genetics of Alzheimer's disease: An update
Brouwers, N., Sleegers, K., & Van Broeckhoven, C. (2008) · Annals of Medicine · doi:10.1080/07853890802186905 · Cited by 208
Jensen, M., Schr�der, J., Blomberg, M., Engvall, B., Pantel, J., Ida, N., Basun, H., Wahlund, L.-O., Werle, E., Jauss, M., et al. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199904)45:4<504::aid-ana12>3.0.co;2-9 · Cited by 214
Amyloid β-protein toxicity and oxidative stress in Alzheimer's disease
Behl, C. (1997) · Cell and Tissue Research · doi:10.1007/s004410050955 · Cited by 211
“Such mutations can be linked to familial forms of AD and have been shown to cause the disease in a fully penetrant fashion similar to APP mutations (Duff et al. 1996; Citron et al. 1997; for a review see Hardy 1997).”
BackgroundStructural studies of soluble oligomers of the alzheimer β-amyloid peptide
Huang, T. H. J., Yang, D.-S., Plaskos, N. P., Go, S., Yip, C. M., Fraser, P. E., & Chakrabartty, A. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3559 · Cited by 212
Self-citationAmyloid-β and Tau at the Crossroads of Alzheimer’s Disease
Gallardo, G., & Holtzman, D. M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9358-8_16 · Cited by 198
Endoproteolytic Cleavage and Proteasomal Degradation of Presenilin 2 in Transfected Cells
Kim, T.-W., Pettingell, W. H., Hallmark, O. G., Moir, R. D., Wasco, W., & Tanzi, R. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.17.11006 · Cited by 210
Neurofilament protein in cerebrospinal fluid: A marker of white matter changes
Sjögren, M., Blomberg, M., Jonsson, M., Wahlund, L. ‐., Edman, Å., Lind, K., Rosengren, L., Blennow, K., & Wallin, A. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1242 · Cited by 209
Molecular biology and genetics of Alzheimer's disease
St George-Hyslop, P. H., & Petit, A. (2005) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2004.10.013 · Cited by 210
Endoproteolytic Processing and Stabilization of Wild-type and Mutant Presenilin
Ratovitski, T., Slunt, H. H., Thinakaran, G., Price, D. L., Sisodia, S. S., & Borchelt, D. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24536 · Cited by 206
Full genome screen for Alzheimer disease: Stage II analysis*
Myers, A., Wavrant De‐Vrieze, F., Holmans, P., Hamshere, M., Crook, R., Compton, D., Marshall, H., Meyer, D., Shears, S., Booth, J., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10183 · Cited by 207
Presenilin, Notch, and the genesis and treatment of Alzheimer's disease
Selkoe, D. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211352598 · Cited by 203
Self-citationThe evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms☆
Finch, C. E., & Sapolsky, R. M. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00053-6 · Cited by 206
Smith, M. A. (1998) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)60607-8 · Cited by 194
Russo, C., Violani, E., Salis, S., Venezia, V., Dolcini, V., Damonte, G., Benatti, U., D'Arrigo, C., Patrone, E., Carlo, P., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01107.x · Cited by 198
“…are the primary components of senile plaques and are considered to be directly involved in the pathogenesis and progression of AD, an hypothesis supported by genetic studies (Glenner and Wong 1984; Borchelt et al. 1996; Lemere et al. 1996; Mann and Iwatsubo 1996; Citron et al. 1997; Selkoe 2001).”
BackgroundIn vivo reduction of amyloid-β by a mutant copper transporter
Phinney, A. L., Drisaldi, B., Schmidt, S. D., Lugowski, S., Coronado, V., Liang, Y., Horne, P., Yang, J., Sekoulidis, J., Coomaraswamy, J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2332851100 · Cited by 205
Self-citationEmerging roles of pathogens in Alzheimer disease
Miklossy, J. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002006 · Cited by 201
“39), mutations in these pathogenic genes alter the processing of APP and result in an increase in amyloidogenic A β 1 – 42 and A β 1 – 43 (Refs 50, 52, 53, 54, 55, 56, 57, 58, 59).”
BackgroundHarigaya, Y., Saido, T. C., Eckman, C. B., Prada, C.-M., Shoji, M., & Younkin, S. G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3490 · Cited by 202
Wolfe, M. S., De Los Angeles, J., Miller, D. D., Xia, W., & Selkoe, D. J. (1999) · Biochemistry · doi:10.1021/bi991080q · Cited by 202
Self-citationCorrelation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice
Gordon, M. N., King, D. L., Diamond, D. M., Jantzen, P. T., Boyett, K. V., Hope, C. E., Hatcher, J. M., DiCarlo, G., Gottschall, W. P. E., Morgan, D., et al. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00249-9 · Cited by 198
“Thus far, mice expressing mPS1 transgenes alone have not been found to deposit A b, although brain concentrations of the long A b variant(s) are elevated [6,10,21].”
BackgroundAPP processing and amyloid deposition in mice haplo-insufficient for presenilin 1
Jankowsky, J. L., Slunt, H. H., Gonzales, V., Jenkins, N. A., Copeland, N. G., & Borchelt, D. R. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.09.008 · Cited by 191
Steiner, H., Capell, A., Pesold, B., Citron, M., Kloetzel, P. M., Selkoe, D. J., Romig, H., Mendla, K., & Haass, C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.48.32322 · Cited by 195
Self-citationWong, T. P., Debeir, T., Duff, K., & Cuello, A. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02706.1999 · Cited by 196
The γ-Secretase Complex: Membrane-Embedded Proteolytic Ensemble
Wolfe, M. S. (2006) · Biochemistry · doi:10.1021/bi060799c · Cited by 161
Roßner, S. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00044-6 · Cited by 198
Stimulation of α4β2 nicotinic acetylcholine receptors inhibits β-amyloid toxicity
Kihara, T., Shimohama, S., Urushitani, M., Sawada, H., Kimura, J., Kume, T., Maeda, T., & Akaike, A. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00138-3 · Cited by 193
Skoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194
Wen, P. H., Hof, P. R., Chen, X., Gluck, K., Austin, G., Younkin, S. G., Younkin, L. H., DeGasperi, R., Gama Sosa, M. A., Robakis, N. K., et al. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.04.002 · Cited by 189
Zou, K., Yamaguchi, H., Akatsu, H., Sakamoto, T., Ko, M., Mizoguchi, K., Gong, J.-S., Yu, W., Yamamoto, T., Kosaka, K., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1549-07.2007 · Cited by 187
“A high A 42/ A 40 ratio is a major determinant for AD development in familial AD with presenilin mutations (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997).”
BackgroundWeggen, S., & Beher, D. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt107 · Cited by 192
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Yamada, K., & Nabeshima, T. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00081-4 · Cited by 190
Wolfe, M. S. (2007) · EMBO reports · doi:10.1038/sj.embor.7400896 · Cited by 192
Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease
PAKASKI, M., & KALMAN, J. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.06.005 · Cited by 178
Therapeutic strategies for Alzheimer's disease
Wolfe, M. S. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd938 · Cited by 190
Arendt, T. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.007 · Cited by 188
Graeber, M. B., Kösel, S., Egensperger, R., Banati, R. B., Müller, U., Bise, K., Hoff, P., Möller, H. J., Fujisawa, K., & Mehraein, P. (1997) · neurogenetics · doi:10.1007/s100480050011 · Cited by 177
Using Knockout and Transgenic Mice to Study Neurophysiology and Behavior
PICCIOTTO, M. R., & WICKMAN, K. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.4.1131 · Cited by 186
Theuns, J., Brouwers, N., Engelborghs, S., Sleegers, K., Bogaerts, V., Corsmit, E., De Pooter, T., van Duijn, C. M., De Deyn, P. P., & Van Broeckhoven, C. (2006) · The American Journal of Human Genetics · doi:10.1086/504044 · Cited by 188
Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease
Sambamurti, K., Greig, N. H., & Lahiri, D. K. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:1:1:1 · Cited by 185
Leissring, M. A., Paul, B. A., Parker, I., Cotman, C. W., & LaFerla, F. M. (1999) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1999.721061.x · Cited by 162
Annaert, W. G., Esselens, C., Baert, V., Boeve, C., Snellings, G., Cupers, P., Craessaerts, K., & De Strooper, B. (2001) · Neuron · doi:10.1016/s0896-6273(01)00512-8 · Cited by 184
Biology of Aβ Amyloid in Alzheimer's Disease
Wisniewski, T., Ghiso, J., & Frangione, B. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0147 · Cited by 134
Podlisny, M. B., Walsh, D. M., Amarante, P., Ostaszewski, B. L., Stimson, E. R., Maggio, J. E., Teplow, D. B., & Selkoe, D. J. (1998) · Biochemistry · doi:10.1021/bi972029u · Cited by 186
Self-citationMcGowan, E., Sanders, S., Iwatsubo, T., Takeuchi, A., Saido, T., Zehr, C., Yu, X., Uljon, S., Wang, R., Mann, D., et al. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0243 · Cited by 185
Mann, D. M. A., Pickering-Brown, S. M., Takeuchi, A., & Iwatsubo, T. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64688-3 · Cited by 182
VERDILE, G. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.028 · Cited by 169
“Subsequent reports, using in vitro [33,50,51] and in vivo studies with human brain tissue [52,53] and brains from transgenic mice [50,54], have also shown an increased ratio of A 42/40.”
Background
Metadata
- Authors
- Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Toronto (CA)
- McLaughlin Research Institute (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1997-01
- Volume
- 3
- Issue
- 1
- Pages
- 67-72
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2081998222
- Cited by
- 1,271
- References
- 28
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 20 · 2022: 18 · 2021: 26 · 2020: 29 · 2019: 28 · 2018: 20 · 2017: 20 · 2016: 32 · 2015: 35 · 2014: 38 · 2013: 33 · 2012: 49
- FWCI
- 68.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (64309)
- National Institute on Aging (AG 12749, AG-06173, AG 106812, R01AG012749)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- presenilin mutations, Alzheimer's disease, amyloid-beta 42, presenilin 1, presenilin 2, gain-of-function mutations, transgenic mouse model, beta-amyloidosis, early-onset Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cell Line, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, Hippocampus, Humans, Membrane Proteins, Mice, Transgenic, Mutation, Peptide Fragments, Transfection, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.